期刊文献+

新型棘白菌素类抗真菌药——米卡芬净 被引量:4

原文传递
导出
摘要 米卡芬净(micafungin,FK463,商品名Mycamine,由日本藤泽公司研制开发)2002年首次在日本上市,主要用于治疗曲霉菌属和念珠菌属所致的感染,并于2006年得到儿童适应证的批复。它是2005年美国FDA批准上市的第二个棘白菌素类抗真菌药,2006年也已在中国批准上市,对包括对唑类药物耐药的念珠菌属和曲霉菌属具有广谱的抗菌活性,动物实验和临床试验表明其耐受性良好,疗效确切。米卡芬净在美国主要用于治疗深部真菌感染和接受造血干细胞移植(HSCT)患者的预防用药。
出处 《中华内科杂志》 CAS CSCD 北大核心 2007年第4期336-338,共3页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献23

  • 1Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a watersoluble echinecandin-like lipopeptide. J Electron Microsc(Tokyo), 2002, 51 : 247-255.
  • 2Laverdiere M, Hoban D, Restieri C, et al. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother, 2002, 50: 119-123.
  • 3Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother, 2003, 47: 3149-3154.
  • 4Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother, 2000, 44:57-62.
  • 5Uehida K, Nishiyama Y, Yokota N, et al. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo), 2000, 53:1175-1181.
  • 6Nakai T, Uno J, Otomo K, et al. In vitro activity of FK463, a novel lipopeptide antlfungal agent, against a variety of clinically important molds. Chemotherapy, 2002, 48:78-81.
  • 7Chiou CC, Mavrogiorgos N, Tillem E, et al. Synergy,pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycln Z and the echinocandin FK463 aga/nst Aspergillus fumigatus. Antimicrob Agents Chemother,2001,45: 3310-3321.
  • 8Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp. : mierodilution, timekill, and postantifungal-effect studies. Antimicrob Agents Chemother, 2002, 46: 3846-3853.
  • 9Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of dissemi, nated candidiasis and aspergiUosis. Antimicrob Agents Chemother,2000, 44 : 614-618.
  • 10Ito M, Nozu R, Kuramechi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumecystis carinii infection in mice. Antimicrob Agents Chemother, 2000,44 : 2259-2262.

同被引文献31

  • 1乔建军,刘伟,万喆,李若瑜.米卡芬净对分离自中国的念珠菌和曲霉临床株体外抑菌活性的研究[J].中国真菌学杂志,2007,2(1):5-9. 被引量:25
  • 2袁瑾懿(编译),杨帆(校).棘白菌素类的新品种:米卡芬净[J].中国感染与化疗杂志,2007,7(2):111-112. 被引量:6
  • 3重症患者侵袭性真菌感染诊断与治疗指南(2007)[J].中华内科杂志,2007,46(11):960-966. 被引量:448
  • 4无.肺真菌病诊断和治疗专家共识[J].中华结核和呼吸杂志,2007,30(11):821-834. 被引量:657
  • 5AUTMIZGUINE J, GUPTILL JT, COHEN-WOLKPWIEZ M, et a/. Pharmacokinetics and pharmacodynamics of antifungals in children : clinical implications[J]. Drugs, 2014, 74 (8) : 891 - 909.
  • 6LI CC, SUN P, DONG Y, et ol. Population phm'macokinetics and pharmacodynamics of caspofungin in pediatric patients [J]. Antimicrob Agents Chemother, 2011, 55 (5) : 2098-2105.
  • 7LEWIS RE. Current concepts in antifungal pharmacology[J]. Mayo Clin Proc, 2011, 86(8) : 805-817.
  • 8SEIBEL NL, SCHWARTZ C, ARRIETA A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients[J]. Antimicrob Agents Chemo- ther, 2005, 49(8): 3317-3324.
  • 9BELET N, CIFTCI E, AYSEV D, et ol. Invasive Candida infections in children: the clinical characteristics and species distribution and antifungal susceptibility of Candida spp.[J]. Turk J Pediatr, 2011, 53(5): 489-498.
  • 10PFALLER MA, BOYKEN LR, HOLLIS R J, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.[J]. J Clin Microbiol, 2010, 48 (1): 52-56.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部